中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
3期
291-293
,共3页
急性脑梗死%依达拉奉%奥扎格雷钠%C反应蛋白
急性腦梗死%依達拉奉%奧扎格雷鈉%C反應蛋白
급성뇌경사%의체랍봉%오찰격뢰납%C반응단백
Acute cerebral infraction%Edaravone%Ozagrel Sodium%C-reactive protein
目的 探讨依达拉奉联合奥扎格雷钠对急性脑梗死(ACI)患者血浆C反应蛋白(CRP)的影响及疗效.方法 80例ACI患者完全随机分为观察组(依达拉奉+奥扎格雷钠)和对照组(奥扎格雷钠),各40例,进行神经功能缺损评分和临床疗效评定,并检测2组治疗前后血浆CRP的变化.结果 观察组的临床疗效上显著优于对照组,总显效率分别为72.5％、37.5％,总有效率分别为90.0％、80.0％ (x2=10.365,P =0.035).治疗后对照组和观察组的CRP浓度均较治疗前降低[观察组:(4.2±1.0)mg/L比(9.6±2.9)mg/L,t=2.947,P=0.042;对照组:(6.9±0.9) mg/L比(9.9±2.6)mg/L,t=1.85,P=0.047],2组治疗后比较差异有统计学意义(t=-3.127,P＜0.05).结论 依达拉奉联合奥扎格雷钠可通过降低CRP水平来发挥保护脑组织作用.
目的 探討依達拉奉聯閤奧扎格雷鈉對急性腦梗死(ACI)患者血漿C反應蛋白(CRP)的影響及療效.方法 80例ACI患者完全隨機分為觀察組(依達拉奉+奧扎格雷鈉)和對照組(奧扎格雷鈉),各40例,進行神經功能缺損評分和臨床療效評定,併檢測2組治療前後血漿CRP的變化.結果 觀察組的臨床療效上顯著優于對照組,總顯效率分彆為72.5％、37.5％,總有效率分彆為90.0％、80.0％ (x2=10.365,P =0.035).治療後對照組和觀察組的CRP濃度均較治療前降低[觀察組:(4.2±1.0)mg/L比(9.6±2.9)mg/L,t=2.947,P=0.042;對照組:(6.9±0.9) mg/L比(9.9±2.6)mg/L,t=1.85,P=0.047],2組治療後比較差異有統計學意義(t=-3.127,P＜0.05).結論 依達拉奉聯閤奧扎格雷鈉可通過降低CRP水平來髮揮保護腦組織作用.
목적 탐토의체랍봉연합오찰격뢰납대급성뇌경사(ACI)환자혈장C반응단백(CRP)적영향급료효.방법 80례ACI환자완전수궤분위관찰조(의체랍봉+오찰격뢰납)화대조조(오찰격뢰납),각40례,진행신경공능결손평분화림상료효평정,병검측2조치료전후혈장CRP적변화.결과 관찰조적림상료효상현저우우대조조,총현효솔분별위72.5％、37.5％,총유효솔분별위90.0％、80.0％ (x2=10.365,P =0.035).치료후대조조화관찰조적CRP농도균교치료전강저[관찰조:(4.2±1.0)mg/L비(9.6±2.9)mg/L,t=2.947,P=0.042;대조조:(6.9±0.9) mg/L비(9.9±2.6)mg/L,t=1.85,P=0.047],2조치료후비교차이유통계학의의(t=-3.127,P＜0.05).결론 의체랍봉연합오찰격뢰납가통과강저CRP수평래발휘보호뇌조직작용.
Objective To observe the influence on C-reactive protein (CRP) and curative effect of edaravone combined ozagrel sodium in treatment of acute cerebral infraction (ACI).Methods Totally 80 patients with ACI were randomly divided into two groups:observation group ( treated with ozagrel sodium plus edaravone) and control groups ( treated with ozagrel sodium).All patients were scored by Clinical Neurologic Functional Defect Scoring (CNFDS),and the clinical effect was measured.Then serum CRP level was measured within 2 hours before and after treatment.Results After treatment,curative effect exhibited significantly better in observation group compared with control group ( total rate of excellence:72.5％ vs 37.5％,the total efficiency:90％ vs 80％,x2 =10.365,P=0.035).The CRP levels were both decreased in these two groups.In observation group the CRP level decreased significantly from (9.64 ± 2.92 ) mg/L to (4.16 ± 1.05 ) mg/L after treatment ( t =2.947,P =0.042 ),and in control group,it decreased significantly from (9.89 ±2.65) mg/L to 6.88 ±0.92) mg/L after treatment(t =1.85,P =0.047 ).Conclusion Combined therapy of edaravone with ozagrel sodium can protect brain tissue through reducing the CRP level.
